Skip to main content
OpenTrials
Completed

NCT Number: NCT03823014

Use of an External Erectile Device in Transgender Man Following Phalloplasty

The purpose of this study is to test whether an external erectile prosthesis (The Elator™) is a feasible alternative to internal erectile prostheses for transgender men who have undergone a phalloplasty with glansplasty and wish to use their neophallus for sexual penetration. The Elator™ was initially developed for men experiencing erectile dysfunction after prostate cancer. The device consists of two silicone rings connected by a pair of plastic coated rigid metal rods. One ring goes at the base of the penis. The other ring is connected to the rods. This ring is placed behind the glans, and then the rods are connected to the base ring to stretch and provide rigidity to the phallus.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Participation in this study is from participants home.

Boston, Massachusetts, 02115, United States

About this study

There are approximately 1.4 million transgender adults in the United States. Approximately half are transgender men, individuals who have a male gender identity but were assigned female at birth. A national survey of transgender adults found more than half of transgender men have had, or may want, gender affirmation surgery in the form of phalloplasty - the surgical creation of a penis and scrotum. The neophallus created in this manner can be used for standing urination but not for penetrative sex, due to the lack of erectile structures.

Research suggests that one factor limiting interest in phalloplasty is the lack of reliable, durable, and desirable erectile devices. Internal prostheses are the primary method used to attain penile rigidity after phalloplasty. However, these devices carry a significant risk of mechanical failure and other adverse events. The high failure and complication rates associated with internal erectile prostheses demonstrate a need for alternative options for transgender men after phalloplasty. One such option consists of an external erectile prosthesis or support. The Elator™ consists of two silicone rings connected by a pair of plastic coated rigid metal rods. Use of such an external device may be preferable for men who do not wish to undergo additional surgery after phalloplasty, and/or those who have had problems with internal prostheses.

Word of mouth suggests that a number of transgender men have experimented with these devices after phalloplasty, but to date no study has tested the safety and function of external erectile prostheses in this population. Currently, the FDA exempts most external penile rigidity devices from pre-market notification and review. As such, safety and efficacy testing is not required prior to public marketing. However, before medical professionals can feel comfortable recommending these devices to their patients, such testing is clearly indicated.

The proposed pilot study will test whether an external erectile prosthesis (The Elator™) is a feasible alternative to internal erectile prostheses for transgender men after phalloplasty. This study will recruit twenty men who have had a phalloplasty greater than one year prior to the study date, have protective sensation to the tip of their phallus, have a current sexual partner with whom they would like to explore sexual penetration using the neophallus, and who do not currently have an internal erectile prosthesis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Primary study subject must have had a phalloplasty with glansplasty a minimum of 1 year before enrollment and must have protective sensation to the tip of the phallus
  • Primary study subject must be in a relationship in which they are having, or would like to have, penetrative sex with their partner. Partner must also be interested in having penetrative sex with primary subject.
  • Both primary study subject and partner must have (individual) e-mail addresses and access to the Internet to complete surveys
  • Primary study subject must be willing to be contacted by postal mail, in order to receive the device
  • Both subjects must be willing to receive e-mails

Exclusion criteria

  • Either subject or partner does not speak English
  • Primary subject has an internal erectile prosthesis.

Treatment and study plan

Elator

Device

Measurement for device, use of device

Other names: Erector

Primary outcomes

  1. Change in Quality of Sexual Experience Scale

    Time frame: Baseline and at study completion (~1.5 months)

    Brief measure of quality of most recent sexual experience

  2. Change in Relationship Satisfaction Subscale

    Time frame: Baseline and at study completion (~1.5 months)

    Measure of overall relationship satisfaction with romantic partner

  3. Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS)

    Time frame: The intervention period of 4 weeks, assessed at study completion

    Validated measure of satisfaction with erectile dysfunction treatment

Secondary outcomes

  1. Qualitative Device Feedback

    Time frame: The intervention period of 4 weeks, assessed at study completion

    Interview with men and their partners about the experience of using the device (optional)

Sponsors and collaborators

Lead sponsor

Boston Children's Hospital

Other

Registry information

Acronym: ProstHEsis

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Jan 30, 2019
Registry last updated
Jul 21, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.